On the one hand, this is consistent with an earlier finding that BRCA1-mutant breast cancer cell lines do not usually harbor activating mutations in RAS and BRAF oncogenes26, which normally make cells susceptible to MEK inhibitors29, 30, 31. This evidence concerns the gene BRCA1 and breast carcinoma.